These data support the hypothesis that RAS signaling in the TNBC and HER2+ cell lines make use of different downstream effectors (Figure 8) and further define the BC patient population that may ultimately benefit from RAL-targeting therapies. This evidence concerns the gene RALA and breast cancer.